UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 29, 2015
IMMUNOCELLULAR THERAPEUTICS, LTD.
(Exact name of Company as specified in its charter)
| | | | |
| Delaware | | 001-35560 | | 93-1301885 |
| | | | |
(State or other jurisdiction of incorporation or organization) | | (Commission File Number) | | (I.R.S. Employer Identification No.) |
23622 Calabasas Road, Suite
300
Calabasas, California 91302
(Address of Principal Executive
Offices) (Zip Code)
Company’s telephone number, including area code: (818) 264-2300
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions (see General Instruction A.2. below):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 Other Events
On October 29, 2015, ImmunoCellular Therapeutics, Ltd. issued a letter reminding all stockholders of record as of the record date to vote their shares at the Company’s Special Meeting of the Stockholders to be held on November 16, 2015, a copy of which is attached as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| | |
| Exhibit | | Description |
| 99.1 | | Letter to ImmunoCellular Therapeutics, Ltd. stockholders reminding all stockholders of record as of the record date to vote their shares at the Company’s Special Meeting of the Stockholders to be held on November 16, 2015. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | |
| Date: October 30, 2015 | | | | IMMUNOCELLULAR THERAPEUTICS, LTD. |
| | | |
| | | | By: | | /s/ David Fractor |
| | | | | | David Fractor |
| | | | | | Vice President of Finance and Principal Accounting Officer |
